Ucla General Clinical Research Los Angeles, CA - 90095

Ucla General Clinical Research is categorized under Biological Research in Los Angeles, CA and active since 1998.

Ucla General Clinical Research was established in 1998, and today employs 1 to 4, earning Unknown per year. This is a Biological Research business, which does work in the B2B market, and is classified as a Biological Research, under code number 5417115 by the NAICS.

If you are seeking more information, feel free to contact Isidro Salusky, Executive Director at the company’s branch by writing to 10833 Le Conte Avenue # 27-066, Los Angeles, California CA 90095 or by phoning (310) 825-5225. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Ucla General Clinical Research
Contact Person: Isidro Salusky, Executive Director
Address: 10833 Le Conte Avenue # 27-066, Los Angeles, California 90095
Phone Number: (310) 825-5225
Annual Revenue (USD): Unknown
Founded: 1998
Location Type: Branch
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Biological Research
SIC Code: 8731
NAICS Code: 5417115
Share This Business:

Ucla General Clinical Research was started in 1998 to provide professional Biological Research under the SIC code 8731 and NAICS code 5417115. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.

Feel free to contact Isidro Salusky, Executive Director for inquiries that concern Ucla General Clinical Research by calling the company number (310) 825-5225, as your correspondence is most welcome. Additionally, the physical location of the branch of Ucla General Clinical Research can be found at the coordinates 34.07019,-118.45102 as well as the street address 10833 Le Conte Avenue # 27-066 in Los Angeles, California 90095.

For its online presence, you may visit Ucla General Clinical Research’s website at and engage with its social media outlets through on Twitter and on Facebook.